Boehringer Ingelheim Ditches Phase II Alzheimer's Program Post author:Sam Post published:February 8, 2018 Post category:BioPharma Another potential treatment for Alzheimer’s disease has been tossed into the rubbish bin. Source: BioSpace You Might Also Like Millendo Therapeutics Sweeps Up Phase II Asset With Acquisition of Small Biotech December 19, 2017 Late-Breaking BIOTRONIK Study Results To Be Presented At Congress 2017 August 23, 2017 Why Gilead Should Keep an Eye on Juno's New CAR-T Strategy November 16, 2017